IceCure Medical Files for FDA Clearance for Next-Gen Cryoablation System

IceCure Medical Ltd. (Nasdaq: ICCM) has filed a 510(k) submission with the FDA for clearance of its next-generation single probe cryoablation system, the XSense™ System and cryoprobes.

“As our ProSense® single probe cryoablation system builds market traction globally, we continue to develop our technology pipeline with innovative single and multi-probe systems,” commented IceCure’s CEO, Eyal Shamir.

“We believe IceCure is the technological, clinical and market leader in liquid nitrogen-based cryoablation technologies that can have a significant beneficial impact on global healthcare systems by offering safe, effective, patient-friendly and cost-efficient alternatives to more invasive surgical procedures.”

The filing contains a request for clearance for the XSense System in indications including general minimally invasive cryoablation applications for the kidney, liver, fibroadenomas and neurology. IceCure’s ProSense® system has already received FDA clearance for these indications.

IceCure’s ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them in a fast and convenient office-based procedure.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

Share This Article

 

About the Author

IceCure Medical Files for FDA Clearance for Next-Gen Cryoablation System

Catie Corcoran

Biotech Editor